Distinction of ALK fusion gene‐ and EGFR mutation‐positive lung cancer with tumor markers by Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio

Get full text

Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion by Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio

Get full text

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy by Yoshiaki Amino, Siew‐Kee Low, Hironori Ninomiya, Ayu Kiritani, Keiki Miyadera, Sho Kakuto, Takahiro Akita, Ryosuke Tsugitomi, Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio

Get full text

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors by Ryo Ariyasu, MD, Sho Kakuto, MD, Keiki Miyadera, MD, Takahiro Akita, MD, Ayu Kiritani, MD, Ryosuke Tsugitomi, MD, Yoshiaki Amino, MD, Ken Uchibori, MD, PhD, Satoru Kitazono, MD, PhD, Noriko Yanagitani, MD, PhD, Makoto Nishio, MD, PhD

Get full text